916420-44-5

Basic information

• Product Name: 2-Chloro-6-(trifluoromethyl)be
• Synonyms: 2-Chloro-6-(trifluoromethyl)be;2-Chloro-6-(trifluoromethyl)benzoyl chloride, JRD, 97%
• CAS NO: 916420-44-5
• Molecular Formula: C8H3Cl2F3O
• Molecular Weight: 243.01
• Mol File: 916420-44-5.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• Water Solubility: Insoluble in water.
• Sensitive: Moisture Sensitive
• CAS DataBase Reference: 2-Chloro-6-(trifluoromethyl)be(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-6-(trifluoromethyl)be(916420-44-5)
• EPA Substance Registry System: 2-Chloro-6-(trifluoromethyl)be(916420-44-5)

Safety Data

• HazardClass: 8
• Hazardous Substances Data: 916420-44-5(Hazardous Substances Data)

Usage

Uses

The use of pentafluoropropionic anhydride, trifluoromethylbenzoyl chloride and pentafluorobenzoyl chloride gave fluoro-chitin derivatives with 40, 10 and 5% substitution, respectively. Fluorination of chitin was achieved by facile homogenous reaction of chitin solution with diethyl amino sulfur trifluoride.

Upstream product

• 2376-00-3 2-chloro-6-(trifluoromethyl)benzoic acid 

Downstream Products

• 1175300-52-3 1-(2-chloro-6-(trifluoromethyl)phenyl)ethanol 
• 60611-22-5 2-chloro-6-(trifluoromethyl)benzaldehyde 
• 886500-21-6 (2-chloro-6-(trifluoromethyl)phenyl)methanol 

Relevant articles and documents

BICYCLIC HETEROCYCLIC COMPOUNDS AS ROR GAMMA MODULATORS

The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as modulator of retinoid-related orphan receptor gamma t (RORγt). These compounds prevent, inhibit, or suppress the action of RORγt and are therefore useful in the treatment of RORγt mediated disease, disorder, syndrome or condition such as pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, neurodegenerative diseases or cancer.

4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF

The present invention relates to compounds according to Formula I (Formula I), and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.